logo
Plus   Neg
Share
Email

Rexahn Gets European Patent For Cancer Drug Archexin

Rexahn Pharmaceuticals, Inc. (RNN) said Thursday that the European Patent Office has granted the company a patent, EP 1546180, for its clinical development candidate Archexin and its use for inhibiting the activated form of Akt-1 for the treatment of cancer.

Having successfully completed a Phase IIa clinical trial of Archexin in metastatic pancreatic cancer, Rexahn has conducted an extensive scientific, clinical and business analysis of other potential indications for additional Phase IIa clinical trials with the drug.

Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type and plans on updating investors on the tumor type selection and Phase IIa trial timeline in the fourth quarter of 2013.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically... Eli Lilly and Co. (LLY) Tuesday reported a profit for its first-quarter, compared to a loss last year, primarily driven by higher operating income. Quarterly revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products. The company raised its 2018 outlook. Both adjusted earnings per share and revenue for the quarter beat analysts' expectations. Shares of SAP SE were gaining around 3 percent in German trading after the software giant reported Tuesday higher first-quarter profit with strong growth in cloud subscriptions and support revenues. The company further lifted its outlook for fiscal 2018. CEO said, "With an increasing share of predictable revenues, our beyond expectations profitability is cause for even greater shareholder confiden
Follow RTT